Table II.

Univariate log-rank analysis for important clinicopathological variables and epidermal growth factor receptor expression.

			DSS		LRFS		MeFS
Parameter	Variable	No. of cases	No. of events	P-value	No. of events	P-value	No. of events	P-value
Gender	Male	108	20	0.6027	5	0.3096	14	0.1047
	Female	64	11		17		15
Age	<60	65	13	0.3259	7	0.7575	17	0.0052b
	≥60	107	18		15		12
Pre-Tx tumor status (Pre-T)	T1-T2	81	10	0.0484a	7	0.0836	10	0.1288
	T3-T4	91	21		15		19
Pre-Tx nodal status (Pre-N)	N0	125	19	0.0059b	12	0.0025b	18	0.0866
	N1-N2	47	21		10		11
Post-Tx tumor status (Post-T)	T1-T2	86	12	0.0006c	5	0.0056b	8	0.0123a
	T3-T4	86	34		17		21
Post-Tx nodal status (Post-N)	N0	123	31	0.3442	15	0.6267	20	0.8403
	N1-N2	49	15		7		9
Lymphovascular invasion	Absent	157	38	0.0107a	17	0.0023b	26	0.7236
	Present	15	8		5		3
Perineural invasion	Absent	167	43	0.0297a	20	0.0083b	28	0.8157
	Present	5	3		2		1
Cytoplasmic EGFR expression	Low Exp.	132	33	0.6480	16	0.6884	20	0.3363
	High Exp.	40	13		6		9
Nuclear EGFR expression	Low Exp.	135	28	0.0005c	12	0.0014b	18	0.0182a
	High Exp.	37	18		10		11

^aP<0.05

^bP<0.01

^cP<0.001. EGFR-C, cytoplasmic epidermal growth factor receptor; EGFR-N, nuclear epidermal growth factor receptor; Pre-Tx, pre-treatment; Post-Tx, post-treatment; DSS, disease-specific survival; LRFS, local-recurrence-free survival; MeFS, metastases-free survival; Exp., expression.